Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

REM-422

Phase 2Small molecule

RRemix Therapeutics

REM-422 is one of 27 small molecule programs targeting MDS. It is currently in Phase 2.

2

Indications

2

Total Trials

2

Active Trials

26

Competitors

Pipeline

Status by Indication[3][1]

Indication

MDSRecruiting

Adenoid Cystic CarcinomaRecruiting

MDSPhase 1

Recruiting

Adenoid Cystic CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

15 competitors in Adenoid Cystic Carcinoma

#DrugCompanyPhaseTrials

Adriamycin

Afinitor

Lenvima

Keytruda

Padcev

Ellence

Rybrevant

Johnson & Johnson

Zanzalintinib

Becotatug Vedotin

FFudan University

Verzenio

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

MDS

NCT06297941

Q3 2027

PreclinicalRecruiting

Adenoid Cystic Carcinoma

NCT06118086

Clinical

Trials by Indication[1]

MDS1 trial

Study of REM-422 in Patients With AML or Higher Risk MDS

Recruiting·RRemix Therapeutics·Phase 1·NCT06297941·100 enrolled

Adenoid Cystic Carcinoma1 trial

A Phase 1/2, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

Recruiting·RRemix Therapeutics·Preclinical·NCT06118086·125 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for REM-422. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REM-422 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REM-422. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Remix Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRemix Therapeutics

Related News